血友病患者心血管疾病发病率降低:一项为期5年的多国前瞻性研究结果
这项前瞻性多中心观察研究纳入荷兰和英国30岁以上成年血友病患者709例,随访5年,以QRISK2-2011模型预测事件率为对照,比较心血管疾病实际发生率。可计算QRISK评分的579例中,实际发生9例 vs 预测24例(相对危险度0.38,95%CI 0.18-0.80,P=0.01),绝对风险降低2.4%;按需治疗的重型血友病风险降低最明显。
要点
- 579例可评估患者5年实际心血管事件9例 vs QRISK2预测24例,相对危险度0.38(95%CI 0.18-0.80,P=0.01)。
- 绝对风险降低2.4%;按需治疗的重型血友病风险降低最明显。
- 血友病严重程度与心血管疾病发生率之间无统计学显著关系。
核心结论
- 血友病患者中心血管疾病发生率低于预测值,支持血友病对心血管疾病具有保护作用的理论。
研究设计与样本
- 前瞻性、多中心、观察性研究,纳入荷兰和英国年龄>30岁的成年血友病患者,随访5年。
- 共纳入709例患者,其中687例(96.9%)完成5年随访或达到终点。
- 108例患者在入组时无法计算QRISK评分;其余579例将观察到的致死性和非致死性心血管事件与基于QRISK2-2011心血管风险模型预测的事件率进行比较。
- 研究注册号为NCT01303900。
主要发现
- 579例可评估患者中,观察到的5年心血管事件少于预测:9 vs 24(相对危险度0.38;95%CI 0.18-0.80;P=0.01),对应绝对风险降低2.4%。
- 按需治疗的重型血友病风险降低最明显。
- 血友病严重程度与心血管疾病发生率之间无统计学显著关系。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Hemophilia is a congenital bleeding disorder caused by low levels of clotting factor VIII or IX. The life expectancy of people with hemophilia (PWH) has increased with the availability of clotting factor concentrates. At the same time, the incidence of cardiovascular disease (CVD) has increased; in retrospective studies, there are conflicting data regarding if, despite this increase, the incidence is still lower than in the general population. We prospectively compared the incidence of CVD in PWH vs the predicted incidence. This prospective, multicenter, observational study included adult PWH (aged >30 years) from The Netherlands and United Kingdom. They were followed up for a 5-year period, and CVD incidence was compared with a predicted event rate based on the QRISK2-2011 CVD risk model. The primary end point was the observed fatal and nonfatal CVD incidence after 5 years compared with the estimated events and in relation to severity of hemophilia. The study included 709 patients, of whom 687 (96.9%) completed 5 years' follow-up or reached an end point. For 108 patients, the QRISK score could not be calculated at inclusion. For the remaining 579, fewer CVD events were observed than predicted: 9 vs 24 (relative risk, 0.38; 95% confidence interval, 0.18-0.80; P = .01), corresponding with an absolute risk reduction of 2.4%. Severe hemophilia treated on demand had the highest risk reduction. There was no statistically significant relation between severity of hemophilia and incidence of CVD. In hemophilia, a lower-than-predicted CVD incidence was found, supporting the theory that hemophilia protects against CVD. The study is registered at www.clinicaltrials.gov as #NCT01303900.
引用
- Van Der Valk P, Makris M, Fischer K, et al. Reduced cardiovascular morbidity in patients with hemophilia: results of a 5-year multinational prospective study. Blood Adv. 2022. PMID: 34879394. doi:10.1182/bloodadvances.2021005260
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。